Lynparza Blazes PARP Trail In China
Executive Summary
AstraZeneca/Merck & Co’s Lynparza has become the first PARP inhibitor to be approved in China, continuing a recent trend of accelerated reviews and approvals for novel therapies from multinationals in the country.